CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-α

Molecular Endocrinology

Volumn 19, Issue 12, 2005, Pages 2901-2914

  Fan, Meiyun ^a   Park, Annie ^a   Nephew, Kenneth P ^a,b,c,d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY   (United States)

^d Indiana University School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; GELDANAMYCIN; HEAT SHOCK COGNATE PROTEIN 70; HEAT SHOCK PROTEIN 90;

ARTICLE; BREAST CANCER; CANCER CELL; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN INTERACTION; UBIQUITINATION;

BENZOQUINONES; CELL NUCLEUS; DOWN-REGULATION; ESTROGEN RECEPTOR ALPHA; ESTROGENS; GENE EXPRESSION; HSC70 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MUTATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STRUCTURE, TERTIARY; QUINONES; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES;

EID: 28144439277     PISSN: 08888809     EISSN: 08888809     Source Type: Journal    
DOI: 10.1210/me.2005-0111     Document Type: Article

References (52)

1. Barkhem T, Nilsson S, Gustafsson JA 2004 Molecular mechanisms, physiological consequences and pharmacological implications of estrogen receptor action. Am J Pharmacogenom 4:19-28
2. Webb P, Lopez GN, Greene GL, Baxter JD, Kushner PJ 1992 The limits of the cellular capacity to mediate an estrogen response. Mol Endocrinol 6:157-167
3. Klinge CM 2000 Estrogen receptor interaction with coactivators and co-repressors. Steroids 65:227-251
4. Reid G, Denger S, Kos M, Gannon F 2002 Human estrogen receptor-α: regulation by synthesis, modification and degradation. Cell Mol Life Sci 59:821-831
5. Eckert RL, Mullick A, Rorke EA, Katzenellenbogen BS 1984 Estrogen receptor synthesis and turnover in MCF-7 breast cancer cells measured by a density shift technique. Endocrinology 114:629-637
6. Dauvois S, Danielian PS, White R, Parker MG 1992 Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 89:4037-4041
7. Dauvois S, White R, Parker MG 1993 The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 106:1377-1388
8. Devin-Leclerc J, Meng X, Delahaye F, Leclerc P, Baulieu EE, Catelli MG 1998 Interaction and dissociation by ligands of estrogen receptor and Hsp90: the antiestrogen RU 58668 induces a protein synthesis-dependent clustering of the receptor in the cytoplasm. Mol Endocrinol 12:842-854
9. Bagatell R, Khan O, Paine-Murrieta G, Taylor CW, Akinaga S, Whitesell L 2001 Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin Cancer Res 7:2076-2084
10. Stoner M, Saville B, Wormke M, Dean D, Burghardt R, Safe S 2002 Hypoxia induces proteasome-dependent degradation of estrogen receptor α in ZR-75 breast cancer cells. Mol Endocrinol 16:2231-2242
11. Wormke M, Stoner M, Saville B, Safe S 2000 Crosstalk between estrogen receptor α and the aryl hydrocarbon receptor in breast cancer cells involves unidirectional activation of proteasomes. FEBS Lett 478:109-112
12. Alarid ET, Bakopoulos N, Solodin N 1999 Proteasomemediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. Mol Endocrinol 13:1522-1534
13. Laios I, Journe F, Laurent G, Nonclercq D, Toillon RA, Seo HS, Leclercq G 2003 Mechanisms governing the accumulation of estrogen receptor α in MCF-7 breast cancer cells treated with hydroxytamoxifen and related antiestrogens. J Steroid Biochem Mol Biol 87:207-221
14. Alarid ET, Preisler-Mashek MT, Solodin NM 2003 Thyroid hormone is an inhibitor of estrogen-induced degradation of estrogen receptor-α protein: estrogen-dependent proteolysis is not essential for receptor transactivation function in the pituitary. Endocrinology 144:3469-3476
15. Tsai HW, Katzenellenbogen JA, Katzenellenbogen BS, Shupnik MA 2004 Protein kinase A activation of estrogen receptor α transcription does not require proteasome activity and protects the receptor from ligand-mediated degradation. Endocrinology 145:2730-2738
16. El Khissiin A, Leclercq G 1999 Implication of proteasome in estrogen receptor degradation. FEBS Lett 448:160-166
17. Lonard DM, Nawaz Z, Smith CL, O'Malley BW 2000 The 26S proteasome is required for estrogen receptor-α and coactivator turnover and for efficient estrogen receptor-α transactivation. Mol Cell 5:939-948
18. Nawaz Z, Lonard DM, Dennis AP, Smith CL, O'Malley BW 1999 Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci USA 96:1858-1862
19. Wijayaratne AL, McDonnell DP 2001 The human estrogen receptor-α is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem 276:35684-35692
20. Reid G, Hubner MR, Metivier R, Brand H, Denger S, Manu D, Beaudouin J, Ellenberg J, Gannon F 2003 Cyclic, proteasome-mediated turnover of unliganded and liganded ERα on responsive promoters is an integral feature of estrogen signaling. Mol Cell 11:695-707
21. Nonclercq D, Journe F, Body JJ, Leclercq G, Laurent G 2004 Ligand-independent and agonist-mediated degradation of estrogen receptor-α in breast carcinoma cells: evidence for distinct degradative pathways. Mol Cell Endocrinol 227:53-65
22. Stenoien DL, Patel K, Mancini MG, Dutertre M, Smith CL, O'Malley BW, Mancini MA 2001 FRAP reveals that mobility of oestrogen receptor-α is ligand- and proteasomedependent. Nat Cell Biol 3:15-23
23. Marsaud V, Gougelet A, Maillard S, Renoir JM 2003 Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor α (ERα), differentially affect ERα extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells. Mol Endocrinol 17:2013-2027
24. Shao W, Keeton EK, McDonnell DP, Brown M 2004 Coactivator AIB1 links estrogen receptor transcriptional activity and stability. Proc Natl Acad Sci USA 101:11599-11604
25. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M 1997 Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753-758
26. Wijayaratne AL, Nagel SC, Paige LA, Christensen DJ, Norris JD, Fowlkes DM, McDonnell DP 1999 Comparative analyses of mechanistic differences among antiestrogens. Endocrinology 140:5828-5840
27. Htun H, Holth LT, Walker D, Davie JR, Hager GL 1999 Direct visualization of the human estrogen receptor α reveals a role for ligand in the nuclear distribution of the receptor. Mol Biol Cell 10:471-486
28. Pratt WB, Toft DO 1997 Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 18:306-360
29. Lee MO, Kim EO, Kwon HJ, Kim YM, Kang HJ, Kang H, Lee JE 2002 Radicicol represses the transcriptional function of the estrogen receptor by suppressing the stabilization of the receptor by heat shock protein 90. Mol Cell Endocrinol 188:47-54
30. Ballinger CA, Connell P, Wu Y, Hu Z, Thompson LJ, Yin LY, Patterson C 1999 Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol Cell Biol 19:4535-4545
31. Connell P, Ballinger CA, Jiang J, Wu Y, Thompson LJ, Hohfeld J, Patterson C 2001 The co-chaperone CHIP regulates protein triage decisions mediated by heatshock proteins. Nat Cell Biol 3:93-96
32. He B, Bai S, Hnat AT, Kalman RI, Minges JT, Patterson C, Wilson EM 2004 An androgen receptor NH2-terminal conserved motif interacts with the COOH terminus of the Hsp70-interacting protein (CHIP). J Biol Chem 279:30643-30653
33. Li L, Xin H, Xu X, Huang M, Zhang X, Chen Y, Zhang S, Fu XY, Chang Z 2004 CHIP mediates degradation of Smad proteins and potentially regulates Smad-induced transcription. Mol Cell Biol 24:856-864
34. Bloom J, Amador V, Bartolini F, DeMartino G, Pagano M 2003 Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation. Cell 115:71-82
35. Fan M, Nakshatri H, Nephew KP 2004 Inhibiting proteasomal proteolysis sustains estrogen receptor-α activation. Mol Endocrinol 18:2603-2615
36. Xu W, Marcu M, Yuan X, Mimnaugh E, Patterson C, Neckers L 2002 Chaperone-dependent E3 ubiquitin li-gase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci USA 99:12847-12852
37. Grenert JP, Sullivan WP, Fadden P, Haystead TA, Clark J, Mimnaugh E, Krutzsch H, Ochel HJ, Schulte TW, Sausville E, Neckers LM, Toft DO 1997 The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem 272:23843-23850
38. Zhou P, Fernandes N, Dodge IL, Reddi AL, Rao N, Safran H, DiPetrillo TA, Wazer DE, Band V, Band H 2003 ErbB2 degradation mediated by the co-chaperone protein CHIP. J Biol Chem 278:13829-13837
39. King WJ, Greene GL 1984 Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. Nature 307:745-747
40. Stenoien DL, Mancini MG, Patel K, Allegretto EA, Smith CL, Mancini MA 2000 Subnuclear trafficking of estrogen receptor-α and steroid receptor coactivator-1. Mol Endocrinol 14:518-534
41. Huang Z, Nie L, Xu M, Sun XH 2004 Notch-induced E2A degradation requires CHIP and Hsc70 as novel facilitators of ubiquitination. Mol Cell Biol 24:8951-8962
42. Sommer S, Fuqua SA 2001 Estrogen receptor and breast cancer. Semin Cancer Biol 11:339-352
43. Tateishi Y, Kawabe Y, Chiba T, Murata S, Ichikawa K, Murayama A, Tanaka K, Baba T, Kato S, Yanagisawa J 2004 Ligand-dependent switching of ubiquitin-proteasome pathways for estrogen receptor. EMBO J 23:4813-4823
44. Fan M, Long X, Bailey JA, Reed CA, Osborne E, Gize EA, Kirk EA, Bigsby RM, Nephew KP 2002 The activating enzyme of NEDD8 inhibits steroid receptor function. Mol Endocrinol 16:315-330
45. Freeman BC, Yamamoto KR 2002 Disassembly of transcriptional regulatory complexes by molecular chaperones. Science 296:2232-2235
46. Wochnik GM, Young JC, Schmidt U, Holsboer F, Hartl FU, Rein T 2004 Inhibition of GR-mediated transcription by p23 requires interaction with Hsp90. FEBS Lett 560:35-38
47. Morimoto RI 2002 Dynamic remodeling of transcription complexes by molecular chaperones. Cell 110:281-284
48. Pink JJ, Jordan VC 1996 Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 56:2321-2330
49. Fan M, Bigsby RM, Nephew KP 2003 The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-α and essential for the antiproliferative activity of ICI 182,780 in ERα-positive breast cancer cells. Mol Endocrinol 17:356-365
50. Anderson E 2002 The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res 4:197-201
51. Fowler AM, Solodin N, Preisler-Mashek MT, Zhang P, Lee AV, Alarid ET 2004 Increases in estrogen receptor-α concentration in breast cancer cells promote serine 118/104/106-independent AF-1 transactivation and growth in the absence of estrogen. FASEB J 18:81-93
52. Henrich LM, Smith JA, Kitt D, Errington TM, Nguyen B, Traish AM, Lannigan DA 2003 Extracellular signal-regulated kinase 7, a regulator of hormone-dependent estrogen receptor destruction. Mol Cell Biol 23:5979-5988